Zepbound Coupon Update 2026: What's New, What Changed, and How to Use the Latest Savings Programs

Key Takeaways

• The 2026 Zepbound Savings Card raised the Tier 2 self-pay price from $550 to $650 per month for commercial-insured patients without Zepbound coverage (Eli Lilly Zepbound Savings Card 2026 terms).
• The Tier 1 minimum copay held at $25 per fill, with maximum savings adjusted slightly from $475 to about $469 per fill.
• LillyDirect single-dose vial prices stayed flat at $349 (2.5 mg) and $499 (5 mg through 15 mg) for 2026.
• Medicare, Medicaid, TRICARE, VA, and Massachusetts residents remained excluded from the savings card, a constant since program launch.
• Eli Lilly added new dose strengths and bundle options through LillyDirect during 2025, expanding self-pay access for non-commercial patients.

Direct answer (40-60 words)

The 2026 Zepbound coupon update raised the Tier 2 self-pay price from $550 to $650 per month for commercial-insured patients whose plans don't cover Zepbound. The Tier 1 $25 copay floor and 13-fill annual limit stayed the same. LillyDirect vial prices held flat at $349 to $499. Medicare, Medicaid, and Massachusetts residents remain excluded.

Table of contents

1. The 30-second answer
2. What changed in the 2026 Zepbound coupon update
3. What stayed the same
4. New LillyDirect doses and bundle options
5. How the update affects current Zepbound patients
6. Predicted future changes through 2027
7. How to verify your current price at the pharmacy
8. The compounded tirzepatide path for excluded patients
9. FAQ
10. Sources
11. Footer disclaimers

What changed in the 2026 Zepbound coupon update

Three meaningful updates took effect on January 1, 2026.

1. Tier 2 self-pay price increased from $550 to $650 per month. This affects patients with commercial insurance whose plans don't cover Zepbound. The 18% price increase aligns with the broader list price increase (about 2.5%) but is significantly larger, suggesting Eli Lilly is rebalancing the program to maintain net revenue.

2. Maximum per-fill savings dropped from $475 to about $469. A small change but it can matter for patients with high copays. If your commercial-insurance copay was $500 in 2025, the card brought you to $25. If it's $500 in 2026, you'd pay about $31 ($500 minus the new $469 cap). For most patients on plans with normal copays under $469, the change is invisible.

3. The annual fill limit stayed at 13 fills. This was the most-discussed potential change going into 2026 because some industry analysts predicted Eli Lilly would tighten to 11 or 12 fills per year. The 13-fill limit held.

What stayed the same

The 2026 update kept most program features intact.

Tier 1 minimum copay: still $25. The headline number that most patients see hasn't changed. Patients with commercial insurance that covers Zepbound still pay as little as $25 per fill.

13-fill annual limit. Same as 2024 and 2025. The counter resets each January 1.

Eligibility rules. Same exclusions for Medicare, Medicaid, TRICARE, VA, federal employee plans (some), and Massachusetts residents. Same age requirement (18 and older). Same valid prescription requirement.

Application process. Same online enrollment at zepbound.lilly.com. Same card format with Member ID, BIN, PCN, and Group number.

LillyDirect prices. Single-dose vials held at $349 (2.5 mg) and $499 (5 mg through 15 mg). No price increases for cash-pay patients.

Stacking rules. Still can't combine the savings card with GoodRx or other discount cards. Still can pay residual amounts using FSA or HSA funds.

The continuity matters. Most patients won't notice the 2026 update because the $25 copay floor and 13-fill limit are the most-used features.

New LillyDirect doses and bundle options

Through 2025 and into 2026, Eli Lilly expanded the LillyDirect program with new options.

New 12.5 mg single-dose vial. Added in mid-2025 to fill the gap between 10 mg and 15 mg dosing for patients titrating up. Same $499 price point as the other higher doses.

New 15 mg single-dose vial. Available throughout 2025 and 2026 at $499 per month for cash-pay patients.

Multi-month bundle pricing. Eli Lilly introduced a 3-month bundle for the 5 mg through 15 mg doses in late 2025. Patients can pay $1,499 for three months (saving about $4 per month versus monthly pricing). The bundle requires upfront payment and a 3-month prescription.

Direct-to-patient shipping. LillyDirect ships from a Lilly fulfillment partner directly to the patient's address. The 2026 update added expedited 2-day shipping at no extra cost for orders processed before noon Eastern.

Physician partner network. LillyDirect maintains a list of telehealth providers who can prescribe Zepbound for cash-pay patients. The list expanded in 2025 to include providers in all 50 states.

For more on LillyDirect specifically, see our Zepbound LillyDirect guide.

How the update affects current Zepbound patients

The 2026 update shakes out differently depending on which path you're on.

If you're on the Tier 1 $25 copay (commercial insurance covers Zepbound): You probably won't notice any change. Your copay is still $25, your annual fill limit is still 13, and your re-enrollment carried over from 2025 automatically. Just verify on your January or February claim that the card processed correctly at $25.

If you're on the Tier 2 self-pay path (commercial insurance, Zepbound not covered): You'll see the $100 monthly increase from $550 to $650 starting with your first 2026 fill. Total annual cost on this path went from about $7,150 to $8,450 if you fill every month.

If you're on LillyDirect (no insurance or government coverage): No price change. You're still paying $349 (2.5 mg) or $499 (other doses) per month.

If you're on Medicare or Medicaid: You were never eligible for the savings card. Your options remain LillyDirect ($349 to $499/month), insurance copay if your plan covers Zepbound, or compounded alternatives.

If you used all 13 fills in 2025: You started fresh on January 1, 2026. The new fill counter resets, and your Tier 1 or Tier 2 path applies.

The biggest pain point in the 2026 update is the Tier 2 increase. Patients in this group are the most likely to consider switching to LillyDirect ($499 vs $650 for higher doses) or to compounded tirzepatide.

Predicted future changes through 2027

Manufacturer copay programs evolve, and the 2026 update gives some hints about where the 2027 program may go.

Likely directions for 2027:

• Further Tier 2 price increases. The $100 jump in 2026 was significant. Another increase to $700 to $750 in 2027 wouldn't be surprising.
• Possible reduction in annual fill limit from 13 to 11 or 12. Some industry analysts predicted this for 2026 and were wrong; the prediction may carry into 2027.
• LillyDirect expansion to additional payment formats (insurance billing, FSA preauth, employer wellness program integration).
• Tightening of eligibility rules around mid-year insurance changes.

Less likely:

• Increase in the $25 Tier 1 copay floor. This is the headline number Eli Lilly uses in advertising; raising it would damage the program's marketing value.
• Elimination of the savings card entirely. Manufacturer copay programs for high-volume drugs rarely disappear; they get tighter.

These predictions are speculative. Eli Lilly publishes updated terms each January, so check zepbound.lilly.com for current information rather than relying on predictions.

How to verify your current price at the pharmacy

After the 2026 update, the safest way to confirm your price is to ask the pharmacy to run a test claim before your fill.

Step 1. Call your local pharmacy or use the pharmacy's app (Walmart, CVS, Costco, etc.).

Step 2. Ask the pharmacist to run a "test claim" or "trial adjudication" for your Zepbound prescription using your insurance card and your Zepbound Savings Card details.

Step 3. The pharmacist returns three prices: your insurance copay (without the card), your insurance copay with the card applied, and your final out-of-pocket. Most patients see the final number at $25 (Tier 1) or $650 (Tier 2).

Step 4. If the number doesn't match what you expect, the most common issues are: card number entered wrong, prescription written for Mounjaro instead of Zepbound, prior authorization not yet approved, or insurance plan changed since last fill.

Step 5. If insurance is the issue (e.g., a new prior auth requirement), you have options: get the prior auth, switch to LillyDirect for the month, or use a different pharmacy network.

This 5-minute check before each fill prevents the most common sticker shock at the counter.

The compounded tirzepatide path for excluded patients

Patients excluded from the 2026 Zepbound coupon update (Medicare, Medicaid, Massachusetts, no insurance) often look at compounded tirzepatide as a cost alternative.

Typical 2026 compounded pricing:

• FormBlends compounded tirzepatide: $279 to $449 per month
• Other 503A compounding pharmacies: $250 to $500 per month

Compounded vs Zepbound savings card:

Path	Monthly cost	Format	FDA approval
Zepbound + savings card Tier 1	$25	Pen	Yes
Zepbound + savings card Tier 2	$650	Pen	Yes
Zepbound LillyDirect 5+ mg	$499	Vial	Yes
Zepbound LillyDirect 2.5 mg	$349	Vial	Yes
Compounded tirzepatide	$279-$449	Vial	No

The compounded option costs less than Tier 2 self-pay or any LillyDirect dose for most patients. The trade-off is FDA approval status. Compounded medications haven't gone through the FDA's approval process and aren't interchangeable with branded Zepbound.

For patients excluded from the manufacturer programs by Medicare/Medicaid status, compounded tirzepatide is often the most affordable path that maintains continuous treatment. For more, see our compounded vs brand-name guide.

How the 2026 update affects new patients starting Zepbound

If you're starting Zepbound for the first time in 2026, the program experience differs from prior years.

Onboarding flow (2026):

1. Get a Zepbound prescription from a licensed provider.
2. Visit zepbound.lilly.com to enroll in the savings card or LillyDirect, depending on your insurance status.
3. If commercial insurance covers Zepbound, fill at any retail pharmacy with the savings card. Tier 1 ($25) applies.
4. If commercial insurance doesn't cover Zepbound, choose between Tier 2 ($650/month) at retail or LillyDirect vials ($349 to $499/month).
5. If you have Medicare/Medicaid or no insurance, choose between LillyDirect or compounded alternatives.

Things new patients should know:

• The savings card requires a Zepbound prescription, not Mounjaro. The two drugs are the same molecule but different brand-name approvals.
• LillyDirect requires a separate enrollment from the savings card. They're two different programs.
• Prior authorization can take 3 to 14 days. Plan to start the application early.
• The 13-fill annual limit applies regardless of when you start. If you start in October, you have 13 fills available before 12/31, plus another 13 starting 1/1.

The 2026 update doesn't change the fundamental onboarding process. The financial outcome at the end depends on insurance status, which is the same as it's been since the program launched.

FAQ

What's the latest Zepbound coupon update for 2026? The Tier 2 self-pay price increased from $550 to $650 per month for commercial-insured patients without Zepbound coverage. The Tier 1 $25 minimum copay stayed the same. The 13-fill annual limit stayed the same. LillyDirect vial prices stayed flat at $349 to $499.

Did the Zepbound savings card price change in 2026? The Tier 1 minimum copay stayed at $25, but the maximum per-fill savings dropped from $475 to about $469. The Tier 2 self-pay path increased from $550 to $650 per month. Patients with normal commercial copays under $469 won't notice the change.

Is the Zepbound coupon still $25 in 2026? Yes, for patients with commercial insurance that covers Zepbound. The $25 minimum copay applies up to 13 fills per calendar year. Patients whose copay exceeds about $494 ($25 plus the $469 max benefit) will pay more than $25.

What's the new Zepbound self-pay price? $650 per month for patients with commercial insurance whose plans don't cover Zepbound. $349 to $499 per month through LillyDirect single-dose vials for cash-pay patients without commercial insurance.

Did Medicare patients gain access to the Zepbound coupon in 2026? No. Federal anti-kickback laws still prohibit manufacturer copay coupons for Medicare patients. The exclusion has been in place since the program launched and there's no current policy proposal to change it.

Is there a new LillyDirect bundle in 2026? Eli Lilly introduced a 3-month bundle in late 2025 for 5 mg through 15 mg vials. The bundle is $1,499 for three months (about $4/month savings). It requires upfront payment and a 3-month prescription.

Will the Zepbound coupon get more restrictive in 2027? Likely yes. The 2026 update increased the Tier 2 price by 18%. Industry analysts expect another increase in 2027 plus possible tightening of the annual fill limit. Eli Lilly publishes updated terms each January at zepbound.lilly.com.

Does the 2026 coupon update apply automatically? Yes. Patients who registered in 2025 don't need to reapply. The 2026 program reuses the same Member ID, BIN, PCN, and Group codes. Just verify your card status at zepbound.lilly.com if you're unsure.

Can I still use my 2025 Zepbound coupon in 2026? The card numbers don't expire, but the program terms changed. If you registered in 2025 and use the card in 2026, the 2026 terms (including the $650 Tier 2 price) apply. The card itself is functionally the same.

Did LillyDirect prices change in 2026? No. The 2.5 mg vial held at $349 per month, and the 5 mg through 15 mg vials held at $499 per month. The pricing has been stable since the second half of 2024 and Eli Lilly hasn't signaled an upcoming change.

Should I switch from Tier 2 to LillyDirect after the 2026 update? Maybe. At $650/month for Tier 2 versus $499/month for LillyDirect (for 5 mg and higher doses), LillyDirect saves $151 per month. The trade-offs are vial format instead of pen, and LillyDirect doesn't run insurance claims so the spend doesn't count toward your deductible. Talk to your provider before switching.

What if my commercial plan changes its Zepbound coverage mid-2026? If your plan starts covering Zepbound mid-year, you can switch from Tier 2 to Tier 1 ($25 copay) immediately. If your plan drops Zepbound coverage, you switch from Tier 1 to Tier 2 ($650/month) or to LillyDirect. The card adapts to your current insurance status at each fill.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. Revised 2024.
3. Eli Lilly Zepbound Savings Card 2026 terms and conditions. zepbound.lilly.com. Accessed Q1 2026.
4. Eli Lilly LillyDirect program updates announcement. Eli Lilly press release, December 2025.
5. CMS Office of Inspector General. Special advisory bulletin: pharmaceutical manufacturer copayment coupons. 2014.
6. Massachusetts General Laws Chapter 175H, Section 3 (manufacturer coupon restrictions). 2012.
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for chronic weight management (SURMOUNT-2). Lancet. 2023;402:613-626.
8. Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide for chronic weight management (SURMOUNT-3, lifestyle-induced). JAMA. 2024;331:38-48.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. LillyDirect is a service of Eli Lilly. GoodRx is a trademark of GoodRx Holdings. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.